4//SEC Filing
Jensen Peder 4
Accession 0001209191-21-027411
CIK 0001175505other
Filed
Apr 18, 8:00 PM ET
Accepted
Apr 19, 7:35 PM ET
Size
17.2 KB
Accession
0001209191-21-027411
Insider Transaction Report
Form 4
Jensen Peder
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2021-04-16−12,500→ 0 totalExercise: $22.15→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-04-16−20,000→ 0 totalExercise: $4.14→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-04-16−10,000→ 0 totalExercise: $17.27→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-04-16−15,000→ 0 totalExercise: $6.09→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-04-16−12,500→ 0 totalExercise: $12.70→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-04-16−10,000→ 0 totalExercise: $29.80→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.
- [F2]Not applicable.
Documents
Issuer
FIVE PRIME THERAPEUTICS, INC.
CIK 0001175505
Entity typeother
Related Parties
1- filerCIK 0001518724
Filing Metadata
- Form type
- 4
- Filed
- Apr 18, 8:00 PM ET
- Accepted
- Apr 19, 7:35 PM ET
- Size
- 17.2 KB